What is Beacon Biosignals?
Founded in 2019 and headquartered in Boston, Beacon Biosignals operates at the intersection of neurotechnology and data science. The company specializes in applying sophisticated artificial intelligence to EEG data, effectively unlocking actionable insights for conditions that impact the human brain. By digitizing and standardizing neurophysiological data, Beacon Biosignals provides pharmaceutical and clinical researchers with the tools necessary to develop more effective, targeted therapies.
The company's market position is defined by its ability to bridge the gap between raw neural signals and clinical decision-making. As the demand for objective biomarkers in neurology grows, Beacon Biosignals serves as a critical infrastructure provider, enabling precision medicine for complex disorders ranging from epilepsy to neurodegenerative diseases.
How much funding has Beacon Biosignals raised?
Beacon Biosignals has raised a total of $210M across 3 funding rounds:
Series A
$27M
Series B
$86M
Series B
$97M
Series A (2021): $27M with participation from Casdin Capital and General Catalyst
Series B (2025): $86M led by Innoviva, S32, Catalio Capital Management, General Catalyst, Logos Capital, Nexus NeuroTech Ventures, Indicator Ventures Select I, Takeda Pharmaceutical Company, Casdin Capital, and GV
Series B (2026): $97M supported by Palo Santo, Kicker Ventures, Nexus NeuroTech Ventures, Samsung NEXT, jslhealth.com, and Innoviva
Key Investors in Beacon Biosignals
Palo Santo
Palo Santo is a U.S.-based psychedelic healthcare investment fund focused on increasing the supply of clinically effective and accessible mental health and addiction treatment solutions.
Kicker Ventures
Kicker Ventures is a venture capital fund that invests in companies developing innovative technology solutions to address global healthcare challenges and improve patient outcomes.
Nexus NeuroTech Ventures
Nexus NeuroTech Ventures is dedicated to advancing breakthrough technologies aimed at addressing neurological and psychiatric disorders through clinical neuroscience and biomedical engineering.
What's next for Beacon Biosignals?
Following this major strategic investment, Beacon Biosignals is expected to scale its operational capabilities and deepen its research partnerships. The influx of capital will likely be directed toward enhancing its AI-driven diagnostic pipeline and expanding its clinical trial support services. As the company matures, the focus will shift toward commercializing its platform for broader clinical adoption, potentially setting new standards for how brain-related disorders are monitored and treated.
The strategic alignment with its diverse investor base—which includes both specialized healthcare funds and technology-focused venture firms—provides Beacon Biosignals with the necessary expertise to navigate the complex regulatory and clinical environments inherent in the neurotech industry. Future milestones will likely involve the integration of its technology into standard clinical workflows, further cementing its role as a leader in the digital therapeutics and precision neurology space.
